Hypoxia-induced pulmonary vascular remodeling (HPVR) may lead to persistent pulmonary hypertension of the newborn or cor pulmonale. Endothelin-1 (ET-1), via endothelin-A (ET A ) receptor activation, mediates hypoxic pulmonary vasoconstriction. Our objectives were to develop a newborn mouse model of HPVR and to test the hypothesis that ET A blockade would prevent and reverse HPVR in this model. C57BL/6 mice (n ϭ 64) were exposed to 12% oxygen (HYP group) or room air (RA group) from birth to 2 wk of age. The mice were injected intraperitoneally daily with either BQ-610 (ET A blocker) or vehicle (cottonseed oil) from birth (prevention study) or from 6 d of age (reversal study). HPVR was assessed histologically by pulmonary vascular morphometry by an examiner masked to study group, and by measurement of the right ventricle to left ventricle (RV/LV) thickness ratio. Hypoxia increased medial wall thickness (%WT) in pulmonary arteries Ͻ100 m in diameter and RV/LV thickness ratio. BQ-610 prevented the hypoxiainduced increase in %WT and RV/LV thickness ratio when given from birth, and later therapy partially reversed the hypoxiainduced increase in %WT but not RV/LV thickness ratio. These data show that in the newborn mouse model, chronic hypoxia leads to HPVR that can be completely prevented and partially reversed by ET A blockade. These results indicate that ET-1, acting via ET A receptors, is a mechanism of pathophysiologic significance underlying neonatal HPVR. Development of this newborn mouse model of HPVR facilitates investigation of mechanisms underlying this important and severe disease entity in human infants. In human neonates, chronic hypoxemia increases muscularity of the pulmonary arteries and extends muscularity to more distal arteries (1). Fetal (2) and neonatal (3,4) hypoxemia also leads to pulmonary vascular remodeling in animal models. This pulmonary vascular remodeling may predispose to pulmonary vasoconstriction and PPHN in response to normal changes in oxygenation and acid-base status occurring during labor and early neonatal life. PPHN affects more than 10,000 infants every year in the United States (5) and is associated with considerable morbidity and mortality. Disorders such as bronchopulmonary dysplasia that affect extremely premature newborn infants are also associated with elevated pulmonary arterial pressures and pulmonary vascular remodeling (6). Congenital heart diseases associated with hypoxemia and/or increased pulmonary blood flow may also result in hypoxia-or high flow-induced pulmonary vascular remodeling (7, 8) . In a newborn piglet model, increased vascular smooth muscle tone was the primary cause of elevated pulmonary pressure following 3-5 d of hypoxia exposure, while with longer hypoxia exposure (10 -12 d), structural changes in the pulmonary arteries contributed to the elevated pulmonary arterial pressure (4).
In human neonates, chronic hypoxemia increases muscularity of the pulmonary arteries and extends muscularity to more distal arteries (1) . Fetal (2) and neonatal (3, 4) hypoxemia also leads to pulmonary vascular remodeling in animal models. This pulmonary vascular remodeling may predispose to pulmonary vasoconstriction and PPHN in response to normal changes in oxygenation and acid-base status occurring during labor and early neonatal life. PPHN affects more than 10,000 infants every year in the United States (5) and is associated with considerable morbidity and mortality. Disorders such as bronchopulmonary dysplasia that affect extremely premature newborn infants are also associated with elevated pulmonary arterial pressures and pulmonary vascular remodeling (6) . Congenital heart diseases associated with hypoxemia and/or increased pulmonary blood flow may also result in hypoxia-or high flow-induced pulmonary vascular remodeling (7, 8) . In a newborn piglet model, increased vascular smooth muscle tone was the primary cause of elevated pulmonary pressure following 3-5 d of hypoxia exposure, while with longer hypoxia exposure (10 -12 d) , structural changes in the pulmonary arteries contributed to the elevated pulmonary arterial pressure (4) .
ET-1 is a 21-amino acid polypeptide with strong vasoactive properties that acts via two major receptor isoforms in the vascular bed, ET A and ET B . In the pulmonary artery, ET A receptors located predominantly on vascular smooth muscle cells mediate vasoconstriction, whereas ET B receptors that are located predominantly on endothelial cells mediate vasodilation (9) . A subtype of the ET B receptor (ET B2 ) present on vascular smooth muscle cells also mediates vasoconstriction (10) . The biologic actions of ET-1 vary depending on age (11) , vascular bed, dosage (12) , and species (13) . Specifically, ET-1 has many different functions in the fetus and neonate compared with the adult. ET-1 produces a positive inotropic response in neonatal myocardium but a negative response in the adult rat myocardium (14) . Children have both higher peripheral levels of ET-1 and a higher density of binding sites for ET-1 compared with adults, even though the ratio of ET A /ET B receptors is the same (70:30) (15). ET-1 levels are elevated in newborn infants with PPHN, are positively correlated with disease severity, and decline with resolution of disease in patients who do not require extracorporeal membrane oxygenation (ECMO) (16, 17) .
Our previous studies showed that selective ET A receptor antagonists attenuate acute hypoxia-induced, but not group B streptococcal-induced, pulmonary hypertension in juvenile piglets (18) . We have also shown that selective ET A receptor antagonists attenuate and reverse chronic hypoxic pulmonary hypertensive vascular and cardiac changes in adult rats (19, 20) . However, pulmonary vascular remodeling is more severe in infant compared with adult animals after hypoxic exposure of the same magnitude (21) . Neonatal chronic HPVR differs from adult HPVR with respect to extracellular matrix, pulmonary arterial smooth muscle structure, and vascular reactivity (22) . The objectives of this study were to develop a newborn mouse model of HPVR, and to test the hypothesis that ET A blockade prevents and reverses HPVR in this model. Data from these studies will add to our understanding of the role of ET-1 in the pathogenesis of hypoxia-related pulmonary vascular disease, especially during the phase of rapid postnatal lung development.
METHODS
Experimental animals and animal care. The research protocol was approved by the Institutional Animal Care and Use Committee of the University of Alabama at Birmingham, and all care and handling of the animals was in accordance with National Institutes of Health guidelines. Timed pregnant C57BL/6 mice were obtained from Charles River Laboratories (Wilmington, MA).
Model development. Newborn C57BL/6 mouse pups and their mothers were exposed to normobaric hypoxia or room air from birth in a Plexiglas chamber. A Pro-Ox 110 oxygen controller (Bio-Spherix Ltd., Redfield, NY) servo-controlled the oxygen concentration to the set level by controlling the inflow of a mixture of nitrogen and oxygen gases. The mice were exposed to 14% O 2 ϫ 1 d, 13% O 2 ϫ 1 d, followed by 12% O 2 ϫ 12 d. Our preliminary studies showed that no HPVR occurred if the mice were exposed to 14% O 2 for 2 wk. If exposed to 10% O 2 from birth, excessive mortality was observed by 7 d. At 12% O 2 , a marked increase in mortality was seen only after 14 d, with HPVR evident by 8 -10 d. O 2 concentration (OM-100 oxygen analyzer, Newport Medical Instruments, Newport Beach, CA), humidity, temperature, and barometric pressure (Fisherbrand Digital Barometer, Fisher Scientific, Pittsburgh, PA) within the chamber were monitored continuously. Daily animal maintenance was carried out, with exposure of the animals to room air for Ͻ10 min per day. A standard mouse pellet diet and water were provided ad libitum. After the completion of the period of hypoxia/normoxia exposure, the animals were euthanized and the thorax opened. The trachea was cannulated using a 24-G angiocath and the lungs fixed in inflation using 10% formalin. The right ventricle was also perfused with formalin. After immersion in formalin for 24 h, the samples were transferred to 70% ethanol, and both lungs were placed in a tissue cassette for paraffin embedding. Five-micron sections stained by hematoxylin and eosin (H&E) or elastic stain were used for pulmonary vascular morphometry.
Drug preparation. Five milligrams of BQ 610 (Peptides International, Inc., Louisville, KY) were suspended in 1 mL of cottonseed oil and divided into multiple aliquots of 50 -100 L each and frozen at Ϫ20°C. A fresh aliquot was used for each day of the exposure. The agent/vehicle was given intraperitoneally daily by microsyringe. A dose of 5 L was used for the first 5 d of life, followed by 10 L from d 6 to 10 and 15 L from d 11 to 14. BQ610 was chosen as the ET A antagonist as we had previously noted its efficacy in the juvenile piglet model of hypoxia-induced pulmonary hypertension (18) . Cottonseed oil was used as the vehicle and intraperitoneal administration was done to slow the release and obtain a prolonged effect. The dose of BQ610 (approximately 20 g/g/d body weight ϭ 20 mg/kg/d) was empirically chosen based on the dosage by intraperitoneal injection in existing literature of other ET A blockers of similar potency (23), our previous experience with once-daily dosing of bosentan, a less potent nonselective endothelin blocker (24) , and considerations of IC 50 for BQ 610 (IC 50 for ET A binding of 0.64 nM and 24,000 for ET B binding, indicating high selectivity for ET A receptors and lack of ET B effects even at higher than required dosage) (personal communication from Thukuba Research Institute, Banyu Pharmaceutical Co., Ltd).
Experimental design. This was a 2 ϫ 2 factorial design, with animals exposed to either hypoxia or room air for 2 wk, while also being exposed to BQ-610 or vehicle. For the prevention study, hypoxia/room air exposure and BQ-610/vehicle began at birth and continued for 2 wk, whereas for the reversal study, neonatal mice were exposed to hypoxia or room air for the first week before initiating BQ-610 or vehicle, which was given for the next week. Animals were exposed by litter (each litter exposed to one set of conditions, e.g. hypoxia, BQ-610, prevention study), as randomization within a litter was not possible (skin marking did not prove permanent, and ear tagging is difficult in neonatal mice). Therefore, the sample size varied from group to group. A minimum sample size of six animals per group was the target for this study.
Pulmonary morphometry. Pulmonary vascular morphometry was performed by a modification of the techniques used by Rabinovitch et al. (25) and DiCarlo et al. (19) . Five micron sections stained by H&E or elastin stain were used for pulmonary vascular morphometry using a Nikon Labophot microscope and a reticle eyepiece at 1000ϫ magnification (oil immersion). The wall thickness (WT) of each artery was expressed as a percentage of the vessel diameter % WT ϭ 100 ϫ ͑2 ϫ medial wall thickness͒/external diameter In each tissue section, the wall thickness and vessel diameter of at least 20 consecutive pulmonary arteries cut transversely (longer axis Ͻ50% greater than shorter axis) were determined along two axes perpendicular to each other. Pulmonary arteries were defined as vessels that accompanied airways (veins are interlobular). Vessels Ͻ20 m in external diameter were not considered for analysis, as wall thickness is not uniform in these vessels. All morphometric analysis was carried out by a single examiner masked to the group assignment.
Estimation of right ventricular hypertrophy. Transverse sections of the heart just inferior to the mitral valve leaflet were evaluated for right ventricle (RV) free wall and left ventricle (LV) free wall thickness using a reticle eyepiece at 40ϫ magnification. The calculated RV/LV ratio was considered an index of RV hypertrophy. This procedure of comparison of RV to LV free wall thickness was used, as the more conventional technique comparing RV to LV ϩ septal weight ratio could not be used in the extremely small newborn mouse heart.
RESULTS
Development of the model. Newborn mice were acclimatized to hypoxia by exposure to 14% O 2 ϫ 1 d, 13% O 2 ϫ 1 d, followed by 12% O 2 ϫ 12 d. Despite this, exposure of newborn mice to hypoxia was initially associated with increased mortality in some litters compared with room air controls (initial mortality-room air: 15%, room air ϩ BQ-610: 20%, hypoxia: 40%, hypoxia ϩ BQ-610: 35%). This increased mortality was nearly always in the first 3 d and probably related to maternal neglect rather than hypoxia per se, as the normal nesting and feeding behaviors of the mother were observed to be diminished in the litters that demonstrated increased mortality, and pups that died did not have the stomach distended with milk. Mortality was subsequently significantly reduced in both groups (current mortality-10% in room air and 20% in hypoxia groups; comparable to that in routine nonexperimental conditions) by use of experienced dams, reduction in handling, addition of extra nesting material, and a high-fat breeding diet.
AMBALAVANAN ET AL.
We have presented the data only from the recent litters with the lower mortality. Surviving hypoxia exposed pups were active but were smaller than room air controls. Pulmonary vascular morphometry. A total of 64 mouse pups were evaluated (10 -20 per group). Exposure to chronic hypoxia increased thickness of those pulmonary arteries smaller than 100 m external diameter (Figs. 1, 2) . The magnitude of the hypoxia-induced increase was approximately 43% (median) when all pulmonary arteries (20 - (Fig. 2) . Smaller pulmonary arteries also had proportionately thicker walls compared with larger vessels, even under normoxic conditions (Fig. 2) .
Administration of BQ-610 prevented and partially reversed hypoxia-induced wall thickening (Figs. 1, 2) . BQ-610 completely prevented the hypoxia-induced thickening of pulmonary arteries 20 -100 m (there were an insufficient number of vessels at 100 -199 m for statistical significance, although the trend was similar), but the effect of reversal was significant only in the smaller arteries (20 -50 m) (Fig. 2) . The size distribution of pulmonary arteries was not significantly altered by hypoxia or administration of BQ-610 (i.e. a similar proportion of pulmonary arteries were 20 -50 m or 50-99 m in external diameter) (Fig. 3) . BQ-610 had no effect on pulmonary arteries of room air mice (only the data for the room air BQ-610 prevention group are presented, as the room air BQ-610 reversal group was very similar). There were no effects of the vehicle on medial wall thickness when control animals given vehicle were compared with those not given vehicle, either during room air or hypoxia exposure (data not shown).
Right ventricle to left ventricle wall thickness ratio. Hypoxia increased the relative thickness of the RV free wall compared with the LV free wall. BQ-610 completely prevented this increase, but did not reverse it significantly when initiated after one week of hypoxia exposure (Fig. 4) . BQ-610 did not affect the ventricular wall thickness ratios in the room air exposed animals.
DISCUSSION
The present study describes the development of a newborn mouse model of chronic hypoxia-induced pulmonary vascular remodeling, and demonstrates that endothelin-A receptor blockade prevents and partially reverses the pulmonary vascular remodeling in this animal model. These observations support our hypothesis that ET-1 plays a role in the development of hypoxia-induced pulmonary vascular remodeling via ET A activation. Our previous work (18) in a neonatal piglet model of acute hypoxia demonstrated that treatment with selective ET A blockers (BQ-610 and EMD 122946) decreases pulmonary arterial pressures and pulmonary vascular resistance, without significantly affecting systemic arterial pressures or vascular resistance. Therefore, selective ET A blockers are effective in attenuating both acute (vasoconstriction) and chronic effects of hypoxia (remodeling) on the pulmonary vasculature.
The newborn mouse has many advantages as a model for hypoxia-induced neonatal pulmonary vascular remodeling. Lung development in the human infant from wk 24 of gestation through the first 2 y of age closely parallels lung development of mice in the first two postnatal weeks of age (26, 27) , indicating that this model is appropriate for the evaluation of pulmonary vascular development and remodeling in the infant. The main strength of this model is that modulation of the effects of chronic hypoxia on the developing pulmonary vasculature by expression of specific genes or their absence can be determined using transgenic (either "knockout" or "overexpression") mice. Also, many antibodies and probes are commercially available for use in mice. A larger sample size for lower cost is also possible in view of the many pups in one litter. The small size of the newborn mouse is also an advantage when very expensive compounds such as BQ-610 have to be administered for a prolonged duration.
There are, however, some limitations to the newborn mouse model. As in all animal models, it is possible that, due to interspecies differences, this model may not be directly extrapolated to human neonates, especially as chronic alveolar hypoxia as used in this model is not the etiology of pulmonary hypertension in human neonates. Also, due to age-specific effects, it is possible that fetal hypoxia, hypoxia in the first 2 d after birth, and hypoxia starting a week after birth would all have different physiologic effects. However, differences in hypoxia-induced vascular remodeling (structural effects) are difficult to ascertain with brief hypoxia exposures of less than a week in this model and, hence, age-specific effects are difficult to determine. Hemodynamic measurements are difficult, and isolation of pulmonary vascular cells from newborn mice for investigation of cellular mechanisms is technically challenging. Chronic hypoxic exposure in the developing animal (unlike the adult animal) leads to growth retardation, and concomitant impairment of lung alveolar development (and lung vascular growth) may occur (28, 29) . However, it is not possible to determine what degree of remodeling is directly due to hypoxia per se and how much is due to growth restriction induced by hypoxia.
ET A antagonists prevent fetal or neonatal pulmonary vascular remodeling in other fetal/neonatal animal models. Ivy et al. (30) demonstrated in an ovine fetal preparation of pulmonary hypertension induced by ductal ligation that preventive treatment with BQ-123 attenuated pulmonary hypertension and pulmonary vascular remodeling. Perreault et al. (31) showed that an orally active nonpeptidic ET A antagonist (TBC3711) decreased pulmonary vascular changes induced by chronic hypoxia in the neonatal piglet, when administered from d 3 to d 14 of the hypoxic exposure.
In the current study, the effect of hypoxia was most evident in the smaller "resistance" pulmonary arteries in the newborn mice, which suggests that chronic hypoxia leads to pulmonary hypertension and RV hypertrophy in this animal model in a manner similar to that in human neonates (1) and other neonatal animal models (30, 31) . Selective ET A antagonism attenuated the increase in vessel wall thickness in the same vessels that were most affected by hypoxia, suggesting that this antagonism was specific to the effects of hypoxia. The size distribution of vessels in hypoxia exposed (and hypoxia ϩ ET A blocker-exposed animals) was similar to that of room airexposed animals, indicating that during the 2 wk of exposure to hypoxia, there was no significant trend for the development of pulmonary arteries of smaller external diameter. The increased 
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pulmonary arterial medial wall thickness may be secondary to smooth muscle cell hyperplasia, hypertrophy, or accumulation of extracellular matrix (32) . There is evidence that hypoxia leads to proliferation of specific subpopulations of smooth muscle cells (33) and adventitial fibroblasts (34) in the newborn calf model. The precise mechanisms responsible for the increased thickness of the media with hypoxia remain to be investigated in the mouse model.
Previous work from our laboratory showed that chronic hypoxic exposure increases pulmonary arterial pressure, plasma ET-1 levels, and gene transcript levels for ET-1 and the ET A and ET B receptors in the lung, but not in the great vessels or any other organ (35) . In another study, mice expressing prepro-endothelin-1 promoter-luciferase (PPET-1/LUC) reporter transgenes were exposed to hypoxia for 24 h (36). LUC expression was increased 6-fold in pulmonary tissue but only 2-fold in other tissues. In situ hybridization revealed the strongest transgene expression in the pulmonary vasculature and bronchiolar epithelium. Therefore, hypoxia induces PPET-1, as well as ET receptors in the lung in a selective manner. ET A antagonists, by inhibiting the effect of elevated levels of ET-1 during hypoxic conditions, may not only attenuate vasoconstriction and vascular remodeling by their effects on ET A receptors, but may also augment vasodilation by the unopposed action of ET-1 on ET B receptors, leading to an increased release of nitric oxide (37) . It is probable that ET B2 (constrictor) receptors do not play a major role in HPVR, as selective ET A blockade was able to completely prevent HPVR. Only partial reversal of HPVR and cardiac remodeling was noted when ET A blockade was initiated after the first week. These results are similar to those noted in our previous studies with selective ET A blockers in adult rats (19, 20) .
There have been some preliminary studies on the therapeutic efficacy of selective ET A antagonists in human infants. Two small studies of a total of 10 children noted improvement in pulmonary hemodynamics after administration of BQ-123 for postoperative pulmonary hypertension after corrective surgery for congenital heart disease (38, 39) . However, there have been no randomized controlled trials evaluating ET A antagonists in neonates, infants, or children, although randomized trials in adults using nonselective ET antagonists in primary pulmonary hypertension (40) and selective ET A antagonists in pulmonary hypertension secondary to heart failure (41) have shown benefit despite some adverse effects such as abnormal hepatic function. Our study demonstrating that selective ET A blockers are effective in both prevention and reversal of HPVR therefore has therapeutic significance and indicates that selective ET A antagonists may be candidates for clinical trials in infants with preexisting abnormal pulmonary vascular remodeling, such as infants with PPHN or cor pulmonale.
In conclusion, this study has demonstrated the usefulness of a newborn mouse model for the evaluation of HPVR, and has shown that selective ET A blockers are effective in preventing and in partially reversing HPVR. Further studies are in progress to determine the effects of hypoxic exposure on gene expression in the newborn mouse lung, and to determine whether ET A blockade is able to prevent and reverse these hypoxia-induced alterations. The interactions of ET A blockade with other signaling pathways are also being investigated using transgenic mice. This may enable the identification of new therapeutic targets and new strategies for the management of pulmonary vascular remodeling in the neonate and infant.
